{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:41:35Z","timestamp":1794080495009,"version":"4.8.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To describe the trends in use of antidepressants (ADs), atypical antipsychotics (AAPs), and benzodiazepines (BZDs) among high-, middle-, and low-income countries.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A cross-sectional time-series analysis by country from July 2014 to December 2019 utilizing IQVIA\u2019s Multinational Integrated Data Analysis database was conducted. Population-controlled rates of use were calculated in number of standard units of medications per drug class per population size. The United Nations\u2019 2020 World Economic Situation and Prospects was used to group countries into high-, middle-, and low-income. Percent change in rates of use per drug class was calculated from July 2014 to July 2019. Linear regression analyses were conducted to assess the predictability of percent change in use utilizing a country\u2019s baseline rate of use per drug class and economic status as predictor variables.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 64 countries were included: 33 high-, 6 middle-, and 25 low-income. Average baseline rates of use for ADs in high-, middle-, and low-income countries were 2.15, 0.35, and 0.38 standard units per population size, respectively. For AAPs, rates were 0.69, 0.15, and 0.13, respectively. For BZDs, rates were 1.66, 1.46, and 0.33, respectively. Average percent changes in use for ADs by economic status were 20%, 69%, and 42%, respectively. For AAPs, they were 27%, 78%, and 69%, respectively. For BZDs, they were -13%, 4%, and -5%, respectively. Some associations were found demonstrating that as a country\u2019s economic status increases, percent change of AD (p = 0.916), AAP (p = 0.23), and BZD (p = 0.027) use decreases. Similarly, as baseline rate of use for ADs and AAPs increases, percent change in use decreases with p-values of 0.026 and 0.054, respectively. For BZDs, as baseline rate of use increases, percent change in use increases (p = 0.038).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>High-income countries have a higher rate of treatment utilization compared to low- and middle-income countries (LMICs) with treatment utilization increasing in all countries of interest.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0284389","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:27:22Z","timestamp":1682530042000},"page":"e0284389","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["Global trends in antidepressant, atypical antipsychotic, and benzodiazepine use: A cross-sectional analysis of 64 countries"],"prefix":"10.1371","volume":"18","author":[{"given":"Orges","family":"Alabaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-1466","authenticated-orcid":true,"given":"Shenthuraan","family":"Tharmarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Vigod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":true,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"1","key":"pone.0284389.ref001","first-page":"5","article-title":"The WHO World Mental Health (WMH) surveys.","volume":"6","author":"RC Kessler","year":"2009","journal-title":"Psychiatrie (Stuttg)."},{"key":"pone.0284389.ref002","article-title":"Mental health conditions and substance use: comparing U.S. needs and treatment capacity with those in other high-income countries.","author":"FK Tikkanen R","year":"2020","journal-title":"The Commonwealth Fund."},{"issue":"9590","key":"pone.0284389.ref003","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(07)61239-2","article-title":"Resources for mental health: scarcity, inequity, and inefficiency","volume":"370","author":"S Saxena","year":"2007","journal-title":"Lancet"},{"issue":"21","key":"pone.0284389.ref004","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.291.21.2581","article-title":"Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys","volume":"291","author":"K Demyttenaere","year":"2004","journal-title":"JAMA"},{"issue":"9594","key":"pone.0284389.ref005","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(07)61242-2","article-title":"Scale up services for mental disorders: a call for action","volume":"370","author":"Lancet Global Mental Health Group","year":"2007","journal-title":"Lancet"},{"issue":"9592","key":"pone.0284389.ref006","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(07)61241-0","article-title":"Mental health systems in countries: where are we now?","volume":"370","author":"KS Jacob","year":"2007","journal-title":"Lancet"},{"issue":"9591","key":"pone.0284389.ref007","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(07)61240-9","article-title":"Treatment and prevention of mental disorders in low-income and middle-income countries","volume":"370","author":"V Patel","year":"2007","journal-title":"Lancet"},{"issue":"9590","key":"pone.0284389.ref008","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(07)61238-0","article-title":"No health without mental health","volume":"370","author":"M Prince","year":"2007","journal-title":"Lancet"},{"issue":"9593","key":"pone.0284389.ref009","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(07)61263-X","article-title":"Barriers to improvement of mental health services in low-income and middle-income countries","volume":"370","author":"B Saraceno","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"pone.0284389.ref010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/10673229.2012.649108","article-title":"Global mental health: from science to action","volume":"20","author":"V. Patel","year":"2012","journal-title":"Harv Rev Psychiatry"},{"key":"pone.0284389.ref011","volume-title":"Mental health ATLAS 2020","author":"World Health Organization","year":"2021"},{"key":"pone.0284389.ref012","volume-title":"Comprehensive mental health action plan 2013\u20132030","author":"World Health Organization","year":"2021"},{"issue":"5","key":"pone.0284389.ref013","doi-asserted-by":"crossref","first-page":"e062197","DOI":"10.1136\/bmjopen-2022-062197","article-title":"Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review","volume":"12","author":"C Lunghi","year":"2022","journal-title":"BMJ Open"},{"issue":"6","key":"pone.0284389.ref014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000480456","article-title":"Long-Term and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the Netherlands.","volume":"86","author":"KM Huijbregts","year":"2017","journal-title":"Psychother Psychosom."},{"issue":"5","key":"pone.0284389.ref015","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s11845-021-02833-7","article-title":"Antidepressant medication prescribing patterns in Irish general practice from 2016 to 2020 to assess for long-term use.","volume":"191","author":"A McCool","year":"2022","journal-title":"Ir J Med Sci"},{"issue":"7","key":"pone.0284389.ref016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40261-016-0397-8","article-title":"Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995.","volume":"36","author":"Y Murphy","year":"2016","journal-title":"Clin Drug Investig."},{"issue":"7","key":"pone.0284389.ref017","doi-asserted-by":"crossref","first-page":"e00688","DOI":"10.1016\/j.heliyon.2018.e00688","article-title":"Patterns of benzodiazepines use in primary care adults with anxiety disorders.","volume":"4","author":"MM Tanguay Bernard","year":"2018","journal-title":"Heliyon."},{"issue":"2\u20133","key":"pone.0284389.ref018","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.healthpol.2010.03.008","article-title":"Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use.","volume":"97","author":"CM Cunningham","year":"2010","journal-title":"Health Policy."},{"issue":"10","key":"pone.0284389.ref019","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: A study in 16 countries, 2005\u20132014.","volume":"27","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"pone.0284389.ref020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/ps.2008.59.5.547","article-title":"Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996\u20132006.","volume":"59","author":"S Alessi-Severini","year":"2008","journal-title":"Psychiatr Serv"},{"issue":"12","key":"pone.0284389.ref021","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/pds.4338","article-title":"Trends in utilization of benzodiazepine and Z-drugs in Israel.","volume":"26","author":"E Berman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"pone.0284389.ref022","volume-title":"Health at a glance 2019: Pharmaceutical consumption.","author":"Organization for Economic Co-Operation and Development","year":"2019"},{"issue":"1","key":"pone.0284389.ref023","doi-asserted-by":"crossref","first-page":"e031156","DOI":"10.1136\/bmjopen-2019-031156","article-title":"Patterns of benzodiazepine prescription among older adults in Switzerland: a cross-sectional analysis of claims data","volume":"10","author":"X Luta","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0284389.ref024","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12889-020-08984-z","article-title":"Trends in the consumption rates of benzodiazepines and benzodiazepine-related drugs in the health region of Lleida from 2002 to 2015.","volume":"20","author":"F Torres-Bondia","year":"2020","journal-title":"BMC Public Health."},{"issue":"2","key":"pone.0284389.ref025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine Use and Misuse Among Adults in the United States.","volume":"70","author":"DT Maust","year":"2019","journal-title":"Psychiatr Serv."},{"key":"pone.0284389.ref026","doi-asserted-by":"crossref","first-page":"100719","DOI":"10.1016\/j.jemep.2021.100719","article-title":"Addressing Mental Health Stigma in Low-Income and Middle-Income Countries: A New Frontier for Digital Mental Health.","volume":"19","author":"JA Naslund","year":"2021","journal-title":"Ethics Med Public Health."},{"key":"pone.0284389.ref027","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/bmb\/ldm010","article-title":"Mental health in low- and middle-income countries","author":"V. Patel","year":"2007","journal-title":"Br Med Bull"},{"issue":"3","key":"pone.0284389.ref028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1192\/bjp.bp.114.156786","article-title":"Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors","volume":"207","author":"O Lewer D","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"2","key":"pone.0284389.ref029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jcm7020017","article-title":"Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives.","volume":"7","author":"J Guina","year":"2018","journal-title":"J Clin Med."},{"issue":"22","key":"pone.0284389.ref030","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","article-title":"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts","volume":"163","author":"DM Fick","year":"2003","journal-title":"Arch Intern Med"},{"issue":"2","key":"pone.0284389.ref031","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"M Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"pone.0284389.ref032","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pds.3825","article-title":"Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.","volume":"251","author":"C Huerta","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"pone.0284389.ref033","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/acps.12858","article-title":"Trajectory analysis of anxiolytic dispensing over 10 years among new users aged 50 and older.","volume":"137","author":"P Verger","year":"2018","journal-title":"Acta Psychiatr Scand."},{"issue":"11","key":"pone.0284389.ref034","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jamainternmed.2020.4793","article-title":"Drug Reimbursement Regulation in 6 Peer Countries.","volume":"180","author":"EJ Emanuel","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"pone.0284389.ref035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40545-022-00413-3","article-title":"Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan.","volume":"15","author":"ZUD Babar","year":"2022","journal-title":"J Pharm Policy Pract.Feb 24"},{"key":"pone.0284389.ref036","volume-title":"Neurological and Substance Use Disorders in Non-Specialized Health Settings: Mental Health Gap Action Programme (mhGAP)","author":"mhGAP Intervention Guide for Mental","year":"2010"},{"key":"pone.0284389.ref037","volume-title":"COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide.","author":"World Health Organization","year":"2022"},{"key":"pone.0284389.ref038","article-title":"The implications of COVID-19 for mental health and substance use.","author":"N Panchal","year":"2021","journal-title":"Kaiser Family Foundation."},{"key":"pone.0284389.ref039","author":"UK Government: Office of Health Improvements and Disparities","year":"2020","journal-title":"COVID-19 mental health and wellbeing surveillance: report."},{"issue":"20","key":"pone.0284389.ref040","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1001\/jama.2016.3445","article-title":"Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006\u20132015.","volume":"315","author":"J Wong","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"pone.0284389.ref041","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008.","volume":"20","author":"GC Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5 Suppl B","key":"pone.0284389.ref042","first-page":"S1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.","volume":"18","author":"AR Maher","year":"2012","journal-title":"J Manag Care Pharm."},{"issue":"1","key":"pone.0284389.ref043","doi-asserted-by":"crossref","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in Outpatient Benzodiazepine Prescribing in the United States","volume":"2","author":"SD Agarwal","year":"2019","journal-title":"JAMA Netw Open"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:28:16Z","timestamp":1682530096000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284389"}},"subtitle":[],"editor":[{"given":"Joseph Olusesan","family":"Fadare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284389","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}